MARITIME 1
Background
In the UK obesity and overweight in adults is a serious health concern that increases the risk of many other health conditions. This study is investigating if the medicine Maridebart Cafraglutide (MariTide) is safe, can lower body weight, and can improve weight related conditions for people who have obesity or are overweight but do not have type 2 diabetes.
The study will see if MariTide is better than placebo in reducing body weight and whether it causes any side effects. This study will also look at what doses of MariTide are safe for people to take and how well it is tolerated.
Study aims
This study is a phase 3 randomised, double blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of Maridebart Cafraglutide in adult participants without type 2 diabetes who have obesity or are overweight.
Participants will be in the study for a total of 88 weeks including:
An up to 28 day (4 week/1 month) screening period
A 72 week (about 1.5 years) treatment period
A 12 week (3 month) safety follow up period
Study summary
Study progress
The study is currently recruiting participants.
Amgen Inc.
Delivered by the NIHR Leicestershire and Northamptonshire Commercial Research Delivery Centre (CRDC).
Funding and sponsorship
Study publications
This section will be updated if any publications become available.
Data Protection
Chief investigator: Professor Melanie Davies
For more information, please contact: CRDCLeics&Northants@uhl-tr.nhs.uk
Or call: 0116 2584104